November 2023
Deutsche Bank Trust and Agency Services (TAS) supports on €935m IPO for SCHOTT Pharma
SCHOTT Pharma AG & Co KGaA (SCHOTT Pharma), together with its shareholder, SCHOTT AG (SCHOTT Group), priced its Initial Public Offering (IPO) on the Frankfurt Stock Exchange. This was the largest Western European IPO in 2023 at the time of its announcement by Deutsche Börse on 28 September 2023.1
Deutsche Bank’s Investment Bank acted as a joint global coordinator and joint bookrunner for the transaction. In support of the IPO, Deutsche Bank TAS acted as retail coordinator, as well as listing agent for the admission of shares to Frankfurt Stock Exchange and to collective safe custody with Clearstream Banking, Frankfurt.
The all-secondary offering consisted of 30.1 million existing shares (base deal) and up to 4.5 million secondary greenshoe shares (15% of base deal size). At the offer price of €27.00, the total offering of 34.6m shares represented a deal size of €935m and a free float of 23% (post greenshoe).
“This deal is a fantastic example of our Global Hausbank strategy to support our clients holistically across Deutsche Bank’s full product suite. We are delighted to support SCHOTT Pharma on their successful IPO,” said Jason Connery, Head of TAS EMEA at Deutsche Bank.
SCHOTT Pharma is a global leader for drug containment solutions and delivery systems with a pure-play focus on injectable drugs. The company’s portfolio ranges from prefillable glass, polymer syringes to cartridges, vials, and ampoules and serves the top 30 leading pharma manufacturers. With its high-value solutions (HVS), the company capitalises on multiple long-term pharma trends, including the rise of mRNA vaccination, GLP-1 drugs used to treat diabetes or obesity and the general product shift in Pharma towards ready-to-use solutions and more flexible filing lines. For further information about SCHOTT Pharma please visit: https://www.schott-pharma.com